IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
IQVIA (NYSE:IQV) has launched One Home for Sites™, a new technology platform designed to streamline and integrate the various systems and tasks required by clinical research sites. This platform acts as a single sign-on and dashboard, reducing the overload of multiple software applications, thereby freeing up time for site staff to focus on patient recruitment and treatment. One Home for Sites is currently in Beta testing and being piloted by IQVIA Prime Sites, with input from over 100 site personnel. The platform aims to enhance site productivity and accelerate the delivery of new treatments by acting as a neutral aggregator and communicator among various clinical applications.
- Launch of One Home for Sites™ could streamline clinical trial processes, increasing efficiency.
- Beta testing and piloting indicate thorough initial testing phase with feedback integration from site personnel.
- Potential increase in site capacity may allow more trials to be managed simultaneously, enhancing revenue potential.
- Collaboration with clinical technology vendors and pharmaceutical companies suggests comprehensive industry support.
- Reduction in technology overload may improve patient recruitment and treatment processes.
- No financial data provided to measure immediate impact on revenue or expenses.
- Beta testing phase indicates that the product is not yet fully available, delaying potential benefits.
- Success of the platform heavily relies on industry-wide adoption, which is not guaranteed.
- Potential technical issues or integration challenges with existing software applications could arise.
Insights
IQVIA's launch of One Home for Sites represents a significant advancement in clinical trial technology. The platform aims to streamline site operations by consolidating various clinical applications into a single dashboard with single sign-on access. This eliminates the necessity for research sites to juggle multiple usernames and passwords across numerous systems, which is a common pain point that hampers efficiency.
By reducing the technological burden on clinical research sites, One Home has the potential to enable these sites to execute more trials simultaneously and allocate more time to patient care. This harmonization can lead to higher productivity, faster trial completion times and ultimately accelerate the development of new treatments. These improvements are important in the context of the current capacity challenges faced by the clinical research industry.
The platform's neutral aggregator role is particularly noteworthy. It fosters collaboration among pharmaceutical companies and technology vendors, promoting an industry-wide approach to solve systemic issues. This could lead to broader adoption and standardization across the clinical research landscape, further enhancing site efficiency and trial outcomes.
However, the success of One Home will largely depend on the feedback and actual efficiency gains reported by the pilot sites using the platform. If these metrics are positive, widespread adoption could follow, bringing about significant improvements in the clinical trial process.
From a market perspective, IQVIA's One Home for Sites platform addresses a critical inefficiency in the clinical research sector. The fragmentation of clinical trial systems has long been a bottleneck, affecting both the speed and cost-effectiveness of clinical trials. By integrating these systems, One Home stands to provide substantial time and cost savings, which is a strong value proposition for both research sites and trial sponsors.
The involvement of IQVIA Prime Sites in the pilot phase ensures that the platform is tailored to meet the real-world needs of site personnel. This user-centric development approach enhances the likelihood of adoption and satisfaction among end-users. Furthermore, the active engagement of multiple clinical technology vendors and pharmaceutical companies signals strong industry support and collaboration, which is essential for the platform’s success.
For investors, the potential for One Home to become a widely adopted industry standard presents a significant growth opportunity for IQVIA. The platform can drive higher utilization of IQVIA’s broader suite of services, fostering long-term customer loyalty and recurring revenue. Additionally, the efficiency gains and accelerated trial timelines facilitated by One Home could enhance the competitive positioning of IQVIA's clients in the pharmaceutical industry.
While the platform is still in its early stages, the strategic alignment and industry collaboration underpinning One Home suggest promising long-term prospects. Investors should monitor the feedback from the pilot phase and subsequent adoption rates as key indicators of the platform’s impact on IQVIA's financial performance.
Bold initiative to boost the capacity of research sites enters Beta testing and piloting
Clinical research sites manage scores of usernames and passwords in dozens of software applications as they navigate through numerous tasks they must complete each day in conducting clinical trials. This technology overload reduces the time site staff have to recruit and treat patients and the number of trials a site is able to manage simultaneously.
IQVIA One Home for Sites meets this challenge by enabling pharmaceutical companies that sponsor clinical trials, along with their software vendors, to integrate all of the clinical applications they expect a research site to use into one single platform. Acting as a neutral aggregator, connector and communicator, One Home can free up a site’s time to conduct more research and deliver patient care.
“With site capacity becoming a real challenge for the industry, we believe it is our role and responsibility to deliver a solution that brings industry stakeholders together and relieves the burden on research sites,” said Bernd Haas, senior vice president, IQVIA Digital Products and Solutions. “IQVIA One Home for Sites is the only product with a vision and scope broad enough to reverse the negative effects of technology proliferation that is plaguing sites today.”
IQVIA has taken input from more than 100 site personnel in the development of One Home to ensure that the platform provides an experience that meets their needs. IQVIA Prime Sites – clinical trial institutes or networks that are committed to long term relationships with IQVIA to improve and innovate clinical trial delivery – are currently piloting One Home to gather feedback and metrics on user experience and efficiencies gained. Additionally, IQVIA is actively engaged with dozens of clinical technology vendors and pharmaceutical companies that understand an industry-wide approach is the only way to increase site capacity and accelerate the delivery of new treatments to patients.
“There is a vast and disparate landscape of technology solutions that, as a whole, is impacting site users,” said Sharlene Carnegie, senior vice president, Platform, Medidata. “We are pleased to collaborate with IQVIA on One Home for Sites and start bridging the gap between systems to help their sites and sponsors save time and resources.” Medidata, a Dassault Systèmes brand, is one of the first companies to become a One Home for Sites partner.
“One Home is a strategic platform to which my organization is fully committed,” said Richard Staub, president, IQVIA Research & Development Solutions. “Rather than competing with individual products and platforms, it enhances sites’ productivity by aggregating clinical trial systems, and I believe that it will be incredibly valuable to the clinical research space and in the studies we run.”
Visit www.iqvia.com/onehome to learn more about the platform and associated partnership program.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612284720/en/
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
Source: IQVIA
FAQ
What is IQVIA's One Home for Sites™ platform?
How does One Home for Sites™ help clinical research sites?
What stage is the One Home for Sites™ platform currently in?
Who are the key collaborators for One Home for Sites™?
What are the potential benefits of One Home for Sites™ for the clinical research industry?
